Compare Eli Lilly And Co (LLY) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

SOXL trades at $136.81, up 1.24% on the day, amid a bearish technical signal with 17 sell indicators versus 7 buy. The semiconductor sector faces volatility, with recent news highlighting AI-driven demand potential but also capital expenditure concerns from major holdings like TSMC. Support sits at $127, with resistance at $144, indicating a critical juncture for near-term price action.

The outlook remains cautious due to leveraged ETF decay risks and sector-wide headwinds, though AI infrastructure growth offers long-term opportunity. Investors face elevated volatility from semiconductor cycle swings and competitive pressures, requiring careful risk management given the fund's amplified exposure.